@xconomy.com 3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@engadget.com 3 years ago
Telehealth got a huge boost from COVID-19. Now what?
@xconomy.com 3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@techcrunch.com 4 years ago
Paige details first AI pathology tech with clinical-grade accuracy in new research paper
@techcrunch.com 4 years ago
Pitching accuracy rates of over 99% for multiple cancer screens, Thrive launches with $110 million
@techcrunch.com 4 years ago
Using full-body MRIs, Ezra can now detect 11 cancers in men and 13 in women
@xconomy.com 4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 5 years ago
HealthMyne, Developer of Health Records Analytics Software, Adds $15M
@xconomy.com 5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com 5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com 5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com 5 years ago
Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up